Navigation Links
Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
Date:10/4/2010

MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd. (DSP) and SanBio, Inc. (SanBio) today announced that they have entered into an option agreement to co-develop a new cell therapy for stroke recovery.

Under the agreement, DSP has received an option for exclusive U.S. and Canadian marketing rights to SB623.  SB623 is a promising cell therapy drug candidate being developed by SanBio for disabilities caused by stroke for which there are currently no effective therapies.  SB623 is an allogeneic cell product, derived from bone marrow stromal cells isolated from healthy donors.  Unlike autologous cell therapy, which requires individualized cell preparation, SB623 production can be scaled, enabling a more cost effective therapy for stroke patients. In preclinical studies to date, SB623 has dramatically improved function in animal models of stroke disability with no significant adverse effects.  The US FDA has recently permitted the initiation of human clinical trial of this innovative cell therapy.

"We expect to exercise this option based on results of a Phase I/IIa trial, already in preparation, and, if these results are favorable, intend to secure exclusive marketing rights to SB623 in the U.S. and Canada," said Masayo Tada, President and Chief Executive Officer of DSP.  "This therapy is an exciting, innovative approach to a profound unmet need for millions of patients. We believe SB623 can contribute to improved health and well being for people throughout the U.S. and Canada."

"Also, for DSP, this therapy is an excellent strategic fit. Our group has been developing business in North America through our subsidiary Sepracor Inc., soon to be called Sunovion Pharmaceuticals Inc.  The addition of this product should enhance our leadership position in the central nervous system (CNS) field, one of our highest priority therapeutic areas."

Keita Mori, co-CEO of SanBio, said, "DSP is an ideal partner for SanBio, with similar research approaches, scientific priorities and business objectives. We are looking forward to working together closely to realize the enormous potential of SB623 in the North American markets."

About Dainippon Sumitomo Pharma Co., Ltd.: Dainippon Sumitomo Pharma (www.ds-pharma.com) is a multi-billion dollar, top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. DSP aims to produce innovative pharmaceutical products in the CNS field, which has been designated as the key therapeutic area, and the specialty area, designated as a frontier therapeutic area.  DSP has more than 7,000 employees worldwide.

About SanBio: SanBio (www.san-bio.com) is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of regenerative cell therapy products.

About SB623: SB623 is a proprietary cell therapy derived from genetically engineered bone marrow stromal cells (MSCs) obtained from healthy adult donors.  SB623 is implanted directly adjacent to the area damaged by stroke and functions by producing proteins that promote the healing process. The development of SB623 is based on earlier research by Professor Mari Dezawa of Tohoku University.


'/>"/>
SOURCE SanBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
2. PDL BioPharma Completes October 1 Special Dividend Payment
3. Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry
4. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
5. Syndax Pharmaceuticals to Present at BIO Investor Forum
6. ISTA Pharmaceuticals Highlights Clinical Data from REMURAâ„¢ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
7. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers
10. Genesis Biopharma Announces $700K Private Financing
11. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... , March 23, 2017 According to ... products and derivatives market is fragmented due to the presence of a ... as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each ... three companies, collectively, held more than 76% of this market in ... As of ...
Breaking Biology Technology:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):